Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Iodiopathic Choroidal Neovascularization in Young Patients
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- Acronyms INTUITION
- 22 Jul 2019 Status changed from active, no longer recruiting to completed.
- 12 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Jul 2018 Planned End Date changed from 1 Oct 2019 to 1 Feb 2020.